Titan Pharmaceuticals Inc. Message Board
-
-
How much was TTNP down? 80%?
TTNP never goes up on good news and gets hammered on minor negative news. - Reply to
The Stock Should Have Dropped Only About 10% on the Curable CRL
by bolivarsam •Jun 10, 2013 10:04 AMIf Probuphine failed in trial such a drop would be justified. Probuphine met the endpoints. AdCom voted overwhelmingly that Probuphine is safe and effective. A few minor issues need to be resolved.
Are you confusing TTNP with APPA? APPA got a CRL for its only pipeline drug and has a market cap of $120M. Other stocks dropped 5% or 10% on a CRL and some even increased in price. - Reply to
$625M Market Cap for $120M Peak Sales, IF Approved ??? Stop the Insanity!!!
by caracass18 •Jun 6, 2013 8:07 PMWhat does caracass know? According to PropThink, it's $131 million!!!!
"Taking an estimated $120M in peak sales of Zerenex in the U.S. and the EU, plus $11M in royalties on peak sales in Japan (13% peak royalty rate), we arrive at a total $131M for Zerenex revenue to KERX under a base case scenario " - Reply to
Yahoo Needs to INSTALL ..IDIOT Catcher on MBs... Too many are permitted to post Garbege Opinions and they
by beenkip •Jun 8, 2013 3:37 PMThat would ban you from posting.
I'm all for that! -
It's extremely rare that a stock does well after a reverse split. Usually it's followed by additional reverse splits.
CTIC, GNTA, XOMA: cases in point. -
It's the kiss of death.
CLSN has already had a 1 for 15 in 2006. -
Anybody who got suckered into buying over $2 will rue the day. This is headed back down below $1, hence the reverse split proposal.
-
It's no doubt something trivial, probably the terms of a supply agreement.
-
"Probuphine has been shown to be effective with an acceptable safety profile in the following clinical studies:
Two six-month, double-blind, placebo-controlled safety and efficacy trials; one of which included an open label, active control (Suboxone).
In both studies, Probuphine demonstrated superiority to placebo implants, and in the second study, established non-inferiority in comparison to Suboxone.
Two six-month, open-label re-treatment safety trials; and
A pharmacokinetic (relative bioavailability) safety study."
Probuphine as as good as Suboxone. -
Per the February filing:
NUMBER OF SHARES 5 SOLE VOTING POWER - 7,446,205
BENEFICIALLY 6 SHARED VOTING POWER - 0
OWNED BY EACH 7 SOLE DISPOSITIVE POWER - 7,446,205
REPORTING PERSON 8 SHARED DISPOSITIVE POWER - 0
It looks like the sold over 3 million shares some time between February and June. - Reply to
In Simple Terms, What Does the "Rights Plan" Really Mean to a Shareholder?
by gogolddndn •Jun 6, 2013 10:15 AMWith the pps temporarily depressed (until FDA resolution) someone could try to buyout the Company on the cheap. The rights plan bars that from happening.
-
An easy reversal.
-
Reason will prevail.
-
-
You were pumping the stock when it was over $2 back in 2010.
You were defending Sunil at every inept financing deal.
Finally you got something right: you're not an expert, far from it, you are closer to an imbecile. - Reply to
Seems like that RB company wants Probuphine stalled or failed
by threemoremonths •Jun 3, 2013 10:34 AMLooking for answers from someone who has been wrong at every turn is the height of insanity.
- Reply to
Seems like that RB company wants Probuphine stalled or failed
by threemoremonths •Jun 3, 2013 10:34 AMIf you want to give the appearance of impartiality, you deny a frivolous petition with open hand under the table. Ridiculous is: defending a policy that flips reason on its head.
- Reply to
So my question still is this...if braeburn stays are they
by quest876 •May 29, 2013 9:17 AMPer the partnership agreement, Braeburn is on the hook for an undisclosed amount for the cost of any additional trials. If that amount is exceeded, then and only then, Titan's milestones would be reduced by the excess amount.
-
The purpose of dosing studies is to find a safe and effective dose.
Titan has a safe and effective dose.
Why do dosing studies now?
It's a ludicrous request.